The Committee acknowledged with thanks the valuable contribution made to its work by the following members of the WHO Secretariat, WHO Collaborating Centres, institutions, and individuals:

Mr S. Fluss, Health Legislation; Dr E. Griffiths, Biologicals, Division of Drug Management and Policies; Mr S. Holand, Action Programme on Essential Drugs; Dr K. Kimura, Drug Safety, Division of Drug Management and Policies; Mr P.H.L. Lewalle, Computer-Assisted Translation and Terminology; Mr M. Nishizawa, Division of Drug Management and Policies; Dr V. Reggi, Operational Drug Registration, Division of Drug Management and Policies; Mr D. Sato, Division of Drug Management and Policies; Dr J. Schill, Quality Assurance, Division of Drug Management and Policies; Dr T. Sodogandji, Action Programme on Essential Drugs; Dr G. Szalay, Supply Services; Dr M. ten Ham, Drug Safety, Division of Drug Management and Policies; Mr T. Yoshida, Programme on Substance Abuse; Mr E. Wondemagegnehu, Action Programme on Essential Drugs.

WHO Collaborating Centre for Drug Quality Control, Therapeutic Goods Administration Laboratories, Commonwealth Department of Health and Family Services, Woden, Australian Capital Territory, Australia; WHO Collaborating Centre for Drug Quality Assurance, National Institute for the Control of Pharmaceutical and Biological Products, Temple of Heaven, Beijing, China; State Institute for Drug Control, Prague, Czech Republic; WHO Collaborating Centre for Biopharmaceutical Aspects of Drug Quality Control, Biopharmacy Laboratory, Faculty of Pharmacy, University of Clermont-Ferrand, Clermont-Ferrand, France; WHO Collaborating Centre for Stability Studies of Drugs, Regional and University Hospital Centre, Nantes, France; Central Indian Pharmacopoeia Laboratory, Ministry of Health and Welfare, Ghaziabad, India; WHO Collaborating Centre for Drug Information and Quality Assurance of Essential Drugs, Central Drugs Laboratory, Government of India, Calcutta, India; WHO Collaborating Centre for Quality Assurance of Essential Drugs, The National Quality Control Laboratory of Drug and Food, Directorate General of Drug and Food Control, Ministry of Health, Jakarta, Indonesia; Quality Control Department, Mexican Institute of Social Security, Mexico City, Mexico; WHO Collaborating Centre for Drug Quality Control, State Research Institute for the Standardization and Control of Drugs, Ministry of Health, Moscow, Russian Federation; WHO Collaborating Centre for Drug Quality Assurance, Pharmacy Laboratory, Department of Science, Institute of Science and Forensic Medicine, Singapore; WHO Collaborating Centre for Chemical Reference Substances, The National Corporation of Swedish Pharmacies, Central Laboratory, Stockholm, Sweden; WHO Collaborating Centre for International Infrared Reference Spectra, Swiss Federal Institute of Technology, Zurich, Switzerland; WHO Collaborating Centre for Quality Assurance of Essential Drugs, Department of Medical Sciences, Ministry of Public Health, Nonthabury, Thailand.

Professor H.Y. Aboul-Enein, Drug Development Laboratory, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia; Professor J.-M. Aiache, Faculty of Pharmacy, University of Clermont-Ferrand, Clermont-Ferrand, France; Professor R.I. Akubue, Department of Pharmacology and Toxicology, University of Nigeria, Nsukka, Nigeria; Dr S.L. Ali, Association of German Pharmacists' Central Laboratory, Eschborn, Germany; Mrs G. Allen-Young, Pharmaceutical Services, Ministry of Health, Kingston, Jamaica; Dr A. Al Na'amani, Supreme Board of Drugs and Medical Appliances, Ministry of Public Health, Sana'a, Yemen; Dr G. Appelbe, London, England; Dr M. Argenti, National Administration of Medicaments, Food and Medical Technology, Buenos Aires, Argentina; Dr A. Artiges, Council of Europe, European Department for the Quality of Medicines, Strasbourg, France; Professor F. Ballereau, Faculty of Pharmacy, Epidemiology and Public Health, Nantes, France; Mr F.P. Barletta, Division of Standards Development, The United States Pharmacopeial Convention, Inc., Rockville, MD, USA; Dr C. Barnstein, The United States Pharmacopeial Convention, Inc., Rockville, MD, USA; Dr M.C. Becerril-Martinez, United Mexican States Pharmacopoeia, Mexico, Federal District, Mexico; Mr T.M. Berg, Inspectorate for Public Health, Rijswijk, Netherlands; Mr G.H. Besson, Pharmaceutical Inspection Convention, Geneva, Switzerland; Mr R. Bhattacharji, The Narcotics Commissioner of India, Gwalior, India; Professor R. Boudet-Dalbin, Faculty of Pharmaceutical and Biological Sciences of Paris-Luxembourg, Rene Descartes University. Paris, France; Mr D.R. Buckley, GMP Audit and Licensing Section, Conformity Assessment Branch, Therapeutic Goods Administration, Woden, Australian Capital Territory, Australia; Dr J. Cable, Therapeutic Goods Administration Laboratories, Woden, Australian Capital Territory, Australia; Dr D.H. Calam, National Institute for Biological Standards and Control, Potters Bar, Herts., England; Mr G. Catto, World Federation of Proprietary Medicine Manufacturers, London, England; Ms A.M. Cavin, Medical Division, International Committee of the Red Cross, Geneva, Switzerland; Mr P. Chemin, European Community Joint Research Centre, Ispra, Italy: Dr M. Chisale, WHO Regional Office for Africa, Brazzaville, Congo; Mrs V. Christ, Therapeutic Goods Administration, Woden, Australian Capital Territory, Australia; Mrs E.M. Cortes Montejano, Information Service for Drugs, Ministry of Health and Consumer Affairs, Madrid, Spain; Dr C. Coune, Council of Europe, European Department for the Quality of Medicines, Strasbourg, France; Mr M.N. Dauramanzi, Drugs Control Council, Harare, Zimbabwe; Mr J.-F. Dechamp, The European Proprietary Medicines Manufacturers' Association, Brussels, Belgium; Professor J.B. Dressman, Johann Wolfgang Goethe University, Frankfurt (Main), Germany; Miss A. Dulion, National Council of the Pharmacists' Order, Paris, France; Professor P. Eagles, School of Pharmacy, University of the Western Cape, Belleville, South Africa; Dr D.I. Ellsworth, Division of Manufacturing and Product Quality, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, MD, USA; Dr P. Emafo, Benin City, Nigeria; Mr G. Eskens, International Dispensary Association, Amsterdam, Netherlands; Mr J. Famulare, Case Management and Guidance Branch, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, MD, USA; Dr F.Y. Fazli, Social Education and Social Welfare, Ministry of Health, Islamabad, Pakistan; Dr R. Freimanis, Office of Drug Nomenclature, United States Adopted Names Council, American Medical Association, Chicago, IL, USA; Dr H. Fukuda, Society of Japanese Pharmacopoeia, Tokyo, Japan; Professor D. Ganderton, Cheriton Bishop, Devon, England: Dr L.T. Grady, The United States Pharmacopeial Convention, Inc., Rockville, MD, USA: Ms S. Greve, The National Board of Health, Medicines Division, Bronshøj, Denmark: Dr W. Grosse, Corporate Quality Assurance, Eli Lilly and Company, Indianapolis, IN, USA; Professor U. Gunder-Remy, University of Göttingen, Göttingen, Germany; Dr S. Haghighi, Food and Drug Quality Control Laboratories, Ministry of Health, Teheran, Islamic Republic of Iran; Dr A.I. Hag Omer, Drug Quality Control, National Chemical Laboratories, Federal Ministry of Health, Khartoum, Sudan; Mrs M. Hietava, Department of General Affairs, National Agency for Medicines, Helsinki, Finland; Dr H. Hoffmann, Kelkheim im Taunus, Germany; Mr H. Hofstetter, Intercantonal Office for the Control of Medicines, Berne, Switzerland; Mr R.K. Howard, Therapeutic Goods Administration Laboratories, Woden, Australian Capital Territory, Australia; Mr H. Ikäläinen, Department of General Affairs, National Agency for Medicines, Helsinki, Finland; Mrs M. Ikeda, Ministry of Health and Welfare, Japan; Dr D. Jayasuriya, United Nations International Drug Control Programme, New Delhi, India; Professor Jin Shaohong, National Institute for the Control of Pharmaceutical and Biological Products, Ministry of Public Health, Beijing, China: Mr V. Johanson, Nutritional Foods Association of Australia, Deakin, Australian Capital Territory, Australia; Dr E. Keller, Quality Assurance Services, Novartis, Basel, Switzerland; Dr I.O. Kibwage, Drug Analysis and Research Unit, Department of Pharmacy, University of Nairobi, Nairobi, Kenya; Dr D. Kiima, Department of Mental Health, Ministry of Health, Nairobi, Kenya; Mr R.H. King, Division of Standards Development, Technical Services, The United States Pharmacopeial Convention, Inc., Rockville, MD, USA; Dr Q.L. Kintanar, Department of Health, Bureau of Food and Drugs, Muntinlupa, Philippines; Dr E. Kkolos, Pharmaceutical Services, Ministry of Health, Nicosia, Cyprus; Dr W. Kleinert, The Federal Institute for Drugs and Medical Devices, Federal Opium Agency, Berlin, Germany; Dr J. Krämer, Association of German Pharmacists' Central Laboratory, Eschborn, Germany; Professor Y. Krylov, State Pharmacopoeia Committee of the Russian Federation, Ministry of Health, Moscow, Russian Federation; Mr J. Lanet, Qualassur, Paris, France; Mrs N.T. Lanuza, Regulation Division, Department of Health, Bureau of Food and Drugs, Metro Manila, Philippines; Mr P. Lefèvre, Drug Agency, Saint-Denis, France; Dr R. Lindauer, Drug Research and Testing Laboratory, The United States Pharmacopeial Convention, Inc., Rockville, MD, USA; Mr M. Lindroos, Ministry of Social Affairs and Health, Helsinki, Finland; Dr K.L. Loening, Topterm, North American Division, Columbus, OH, USA; Mrs M.-H. Loulergue, Laboratories and Control Directorate, Drug Agency, Saint-Denis, France; Dr R.J.J.C. Lousberg, Inspectorate for Health Care, Rijswijk, Netherlands; Professor B.I. Lyubimov, Research Institute of Pharmacology, Russian Academy of Medical Sciences, Moscow, Russian Federation; Mr E. Magnusson, Pharmaceuticals, Ministry of Health, Reykjavik, Iceland; Dr S. Marrer, Quality Assurance, F. Hoffmann-La Roche Ltd, Basel, Switzerland; Associate Professor L. Martinec, State Institute for the Control of Drugs, Bratislava, Slovakia; Dr I.N. Matondo, Regional Drug Control Laboratory, Harare, Zimbabwe; Mr S. Mattmüller, Hewlett-Packard GmbH, Waldbronn, Germany; Dr G.L. Mattok, Pharmaceutical Chemistry Division, Bureau of Drug Research, Health Protection Branch, Ottawa, Ontario, Canada; Mr I. Mboninyibuka, National Pharmaceutical Office, Bujumbura, Burundi; Mrs N. McClay, Regulatory Affairs and External Liaison, European Generic Medicines Association, Brussels, Belgium; Professor K.K. Midha, University of Saskatchewan, Saskatoon, Canada; Dr N. Miyata, Division of Organic Chemistry, National Institute of Health Sciences, Tokyo, Japan; Dr S. Mizuno, Department of Bioactive Molecules, National Institute of Health, Tokyo, Japan; Professor H. Möller, Hoechst AG, Hoechst Marion Roussel, Frankfurt (Main), Germany; Mrs D. Monk, Scientific and Technical Affairs, Australian Pharmaceutical Manufacturers Association, North Sydney, Australia; Professor R.C. Moreau, Paris, France; Mr F. Mounis, International Technical Cooperation, Médecins sans Frontières, Brussels, Belgium; Mrs N. Naim, Pharmaceutical Services, Ministry of Health, Jalan University, Petaling Jaya, Malaysia; Dr M. Negwer, Berlin, Germany; Dr J.D. Nicholson, Medicines Testing Laboratory, Department of Pharmaceutical Sciences, Royal Pharmaceutical Society of Great Britain, Edinburgh, Scotland; Dr E. Njau, Arusha, United Republic of Tanzania; Professor A.A. Olaniyi, Department of Pharmaceutical Chemistry, University of Ibadan, Ibadan, Nigeria; Dr C. Ondari, Department of Health Sciences, University of Nairobi, Nairobi, Kenya; Dr P.R. Pabrai, Ranbaxy Laboratories Ltd., New Delhi, India; Dr R. Patnaik, Division of Bioequivalence, Office of Generic Drugs, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, MD, USA; Dr J. Portych, Czech Pharmacopoeia Commission, State Institute for Drug Control, Ministry of Health, Prague, Czech Republic; Mrs P. Rafidison, International Pharmaceutical Excipients Council-Europe, Dow Corning France SA, Sophia Antipolis, France; Professor M. Rafiee-Tehrani, College of Pharmacy, University of Medical Sciences, Tehran, Islamic Republic of Iran; Professor L. Rägo, State Agency of Medicines, Tarfu, Estonia; Professor J. Richter, Berlin, Germany; Mr P. Romagnoli, European Generic Medicines Association, Aschimfarma, Milan, Italy; Dr A. Saddem, National Drug Control Laboratory, Ministry of Public Health, Tunis, Tunisia; Dr V. Saliasi, Pharmaceutical Services, Ministry of Health, Tirana, Albania; Dr K. Satiadarma, Bandung, Indonesia; Mr H. Schaepe, United Nations International Drug Control Programme, Narcotics Control Board, Vienna, Austria; Mrs S. Schlabitz, Medicines Control Council, Windhoek, Namibia; Professor J. Schlebusch, Department of National Health and Population Development, Pretoria, South Africa; Dr P.J. Schorn, Council of Europe, European Department for the Quality of Medicines, Strasbourg, France; Dr D. Schwarzenbach, Quality Assurance Services, Novartis, Basel, Switzerland; Dr A. Sheak, Department of Drug Administration, Ministry of Health, Kathmandu, Nepal; Dr M.A. Siewert, Quality Control/Quality Assurance, Hoechst AG, Hoechst Marion Roussel, Frankfurt (Main), Germany; Ms K. Sinivuo, National Medicines Control Laboratory, Helsinki, Finland; Professor C.J.P. Siregar, Bandung, Indonesia; Dr D.S. Skinner, Nonprescription Drug Manufacturers' Association of Canada, Ottawa, Ontario, Canada; Dr M. Smíd, State Institute for Drug Control, Prague, Czech Republic; Ms M. Soaki, Ministry of Health, Nuku'alofa, Tonga; Dr E. Spindler-Kloess, Schönenbuch, Switzerland; Dr V. Srdanovic, United Nations Children's Fund, Copenhagen, Denmark; Mrs L. Stefanini-Oresic, Croatian Institute for Medicines Control, Zagreb, Croatia; Dr D. Steinbach, Bad Homburg, Germany; Dr A. Sulistiowati, National Quality Control Laboratory of Drug and Food, Ministry of Health, Jakarta, Indonesia; Dr S.K. Talwar, Central Indian Pharmacopoeia Laboratory, Ministry of Health and Family Welfare, Ghaziabad, India; Professor R. Taylor, School of Pharmacy, The Gordon University, Aberdeen, Scotland; Dr K.-H, Teichmann, Hoechst AG, Hoechst Marion Roussel, Frankfurt (Main), Germany; Miss A. Thépot, Paris, France; Mr J.-F. Thony, United Nations International Drug Control Programme, Vienna, Austria; Mr C.A.C. Tomé dos Reis, Infarmed, National Institute of Pharmacy and Drugs, Lisbon, Portugal; Professor A. Toumi, Pharmacy and Drugs Directorate, Ministry of Public Health, Tunis, Tunisia: Dr P.G. Treagust, Reference Materials Group, SmithKline Beecham Pharmaceuticals, Worthing, West Sussex, England; Mr R.B. Trigg, British Pharmacopoeia Commission, London, England; Mr S. Tsuda, International Affairs Division, Ministry of Health and Welfare, Tokyo, Japan; Mr M. Tsukano, Ministry of Health, Tokyo, Japan: Professor Tu Guoshi, National Institute for the Control of Pharmaceutical and Biological Products, Ministry of Public Health, Beijing, China; Mr J.L. Turner, Inspection and Enforcement Division, Medicines Control Agency, London, England; Dr V. de Urioste, National Department of Drug, Pharmacy and Laboratories. Ministry of Health, La Paz, Bolivia; Mr S. Uzu, Planning Division, Pharmaceutical Affairs Bureau, Ministry of Health and Welfare, Tokyo, Japan; Dr T. Van Quy, National Institute of Drug Quality Control, Hanoi, Viet Nam; Mr M. Venkateswarlu, Central Government Health Scheme Dispensary Building, Mumbai, India; Dr M. Vernengo, School of Health Sciences, Belgrano University, Buenos Aires, Argentina; Dr J.P. Vora, Karnataka Antibiotics and Pharmaceuticals Ltd, Bangalore, India; Dr I. Vukusic, Podravka-Food, Pharmaceuticals and Cosmetics Industries, Zagreb, Croatia; Dr R. Walters, Cardio-Renal Drug Products, Food and Drug Administration, Rockville, MD, USA; Professor W. Wieniawski, Polish Pharmacopoeia Commission, Warsaw, Poland; Dr C. Wongpinairat, Division of Drug Analysis, Department of Medical Sciences, Ministry of Public Health, Nonthaburi, Thailand; Dr Woo Soo On, Department of Scientific Services, Institute of Science and Forensic Medicine, Singapore.